Once Daily Dosing to Improve Medication Adherence and Patient Satisfaction in Kidney Transplant Recipients

NAActive, not recruitingINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

August 10, 2022

Study Completion Date

December 31, 2024

Conditions
End-Stage Renal Disease
Interventions
DRUG

Conversion to Advagraf

Prograf treated patients will convert to Advagraf using a 1: 1 conversion for a period of one week. The dose will then be titrated based on tacrolimus trough levels obtained 7 days after conversion. Cyclosporine (Neoral) treated patients will initiate Advagraf 0.075 mg/kg/day, 24 hours after their last cyclosporine dose. Participants will be provided with Advagraf and instructed how to start this new medication

DRUG

conversion of non-immunosuppressant drugs to once daily

"* Conversion of anti-hypertensive medications: converted to once daily alternatives with the goal of maintaining blood pressure at the same or lower level prior to conversion.~* Conversion of all other medications: changed to once daily formulations of the same medication or a once daily alternative."

DRUG

Conversion to once daily MPA

"* Conversion to once daily MPA: Patients taking mycophenolate mofetil (MMF) will receive 1.0 gram once daily, while patients receiving Myfortic will receive 720 mg once daily.~* Conversion to once daily Myfortic: Patients prescribed proton pump inhibitors (PPIs) and MMF will be switched to equivalent dose Myfortic for a period of one month prior to conversion to once daily MPA.~* Patients taking azathioprine will be maintained on the same dose.~* Patients will be maintained on the same prednisone dose."

Trial Locations (3)

V5Z 4H4

BC Children Hospital, Vancouver

Unknown

St. Paul's Hospital, Vancouver

Vancouver General Hospital, Vancouver

All Listed Sponsors
collaborator

Astellas Pharma Canada, Inc.

INDUSTRY

lead

University of British Columbia

OTHER

NCT02426502 - Once Daily Dosing to Improve Medication Adherence and Patient Satisfaction in Kidney Transplant Recipients | Biotech Hunter | Biotech Hunter